Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Amminger

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Psychological Medicine|August 23, 2011
Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 yearsM Álvarez-Jiménez, J F Gleeson, L P Henry, et al.
Translational Psychiatry|May 2, 2013
Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosisC A Bousman, A R Yung, C Pantelis, et al.
Molecular Psychiatry|March 13, 2013
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosisS Smesny, B Milleit, U-C Hipler, et al.
Trials|November 30, 2019
ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosisS M Cotton, M Berk, A Watson, et al.
Current Pharmaceutical Design|January 14, 2012
Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorderA Bechdolf, A Ratheesh, S J Wood, et al.
Translational Psychiatry|August 30, 2017
PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophreniaM A Di Biase, A Zalesky, G O'keefe, et al.
Schizophrenia Research|October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quoM J McHugh, P D McGorry, H P Yuen, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Schizophrenia Research|December 24, 2019
Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomesS Youn, L J Phillips, G P Amminger, et al.
Early Intervention in Psychiatry|July 30, 2013
Transitions Study of predictors of illness progression in young people with mental ill health: study methodologyR Purcell, A F Jorm, I B Hickie, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Psychological Medicine|August 23, 2011
Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 yearsM Álvarez-Jiménez, J F Gleeson, L P Henry, et al.
Translational Psychiatry|May 2, 2013
Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosisC A Bousman, A R Yung, C Pantelis, et al.
Molecular Psychiatry|March 13, 2013
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosisS Smesny, B Milleit, U-C Hipler, et al.
Trials|November 30, 2019
ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosisS M Cotton, M Berk, A Watson, et al.
Current Pharmaceutical Design|January 14, 2012
Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorderA Bechdolf, A Ratheesh, S J Wood, et al.
Translational Psychiatry|August 30, 2017
PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophreniaM A Di Biase, A Zalesky, G O'keefe, et al.
Schizophrenia Research|October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quoM J McHugh, P D McGorry, H P Yuen, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Schizophrenia Research|December 24, 2019
Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomesS Youn, L J Phillips, G P Amminger, et al.
Early Intervention in Psychiatry|July 30, 2013
Transitions Study of predictors of illness progression in young people with mental ill health: study methodologyR Purcell, A F Jorm, I B Hickie, et al.
Pageof 5